The Latest Breaking News from FDA

Bristol Myers Squibb (NYSE:BMY) and 2seventy bio (NASDAQ:TSVT) announced positive topline results from KarMMa-3, a Phase 3 study evaluating Abecma (idecabtagene vicleucel) compared to standard combination regimens in adults with multiple myeloma that is relapsed and refractory. Bristol Myers shares traded in a range of $73.95 to $75.32 on a day volume…

Here's a roundup of top developments in the biotech space over the last 24 hours:

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method.

Merck & Co.’s Januvia, a popular diabetes drug, was found to be contaminated with a potential carcinogen.

As monkeypox cases continue to increase among high-risk people, federal officials on Tuesday announced they will stretch limited vaccine supplies by giving just one-fifth the current dosage.

The FDA has issued emergency authorisation for a dosage technique that would allow more shots of vaccine per vial.

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Relmada Therapeutics’ (NASDAQ:RLMD) lead asset REL-1017 as a monotherapy for the treatment major depressive disorder (MDD). Relmada shares traded in a range of $26.02 to $27.96 on a day volume of 173.79 thousand shares, closed regular trading…

Washington (AFP) - US health authorities on Tuesday authorized a new procedure for injecting the monkeypox vaccine that should make it possible to inoculate more people with the same amount of the drug, at a time when doses are running short in the country. 

The Biden administration is allowing the shot to be given between layers of skin — a method that only requires a fifth of the full dose — in order to increase vaccinations and slow the outbreak.